Welcome to the Exercise Oncology/Oncology Nutrition (EON) Network!
Our goals:
- Support the research needed to develop evidence-based practice guidelines in both exercise oncology and oncology nutrition during cancer treatment
- Facilitate communication between the exercise oncology and oncology nutrition communities to achieve the joint goal of improving cancer treatment outcomes
- Encourage communication between researchers and clinicians working with people receiving cancer treatment
We are excited to offer this new webinar series and networking opportunity, the Exercise Oncology/Oncology Nutrition (EON) Network, coordinated by the NCI-funded Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) Consortium.
News
A monthly EON Network email with information on relevant upcoming events, summaries of recently published research of interest to the exercise oncology and oncology nutrition fields, and relevant research funding opportunities.
Webinars
Invitations to the quarterly webinar series on topics of interest to exercise oncology and oncology nutrition researchers and clinicians.
(Continuing education credits are being requested for these webinars, and webinars will be recorded and archived on the EON Network website.)
(Continuing education credits are being requested for these webinars, and webinars will be recorded and archived on the EON Network website.)
Resources
An EON Resources page with information that is relevant to exercise oncology and oncology nutrition researchers and clinicians.
Upcoming Webinars
April 9, 2026, 2 PM ET
Coffee consumption and improved colorectal cancer survivorship: from observational to interventional studies
Observational findings from several independent cohorts have consistently shown a beneficial association of coffee consumption after diagnosis with better survival outcomes among patients with colorectal cancer. In support of these data, coffee has been linked to lower risk of metabolic disorders, lower inflammation, and favorable blood biochemical profiles. While the components in coffee that drive these benefits remain unknown, studies of metabolomics and microbiome have identified potential molecules and mechanisms of action underlying coffee's beneficial effects. These data altogether have motivated the conduct of the first randomized control trial of coffee consumption among colorectal cancer survivors (the COMMENCER trial). In this presentation, Dr. Song will review the existing data, present the COMMENCER trial, and discuss the future directions.
The George Washington University School of Medicine and Health Sciences designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ for physicians, physician assistants, and nurse practitioners.
The George Washington University School of Medicine and Health Sciences designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ for physicians, physician assistants, and nurse practitioners.